EFFECTOR Therapeutics Inc. - notizie pubblicate 226 - letture 2.739
EFFECTOR THERAPEUTICS INC.
Amendment to Current Report - Form 8-K/A
8-k/a united states securities and exchange commission washington, d.c. 20549 form 8-k/a (amendment no. 1) current report pursuant to section 13 or 15(d) of the securities exchange ...
EFFECTOR THERAPEUTICS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
10-q united states securities and exchange commission washington, dc 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange act ...
EFFECTOR THERAPEUTICS INC.
Material Agreement - Form 8-K
Item 1.01 entry into a material definitive agreement. on may 9, 2024, effector therapeutics, inc. (the "company") entered into an at the market offering agreement (the &q ...
EFFECTOR THERAPEUTICS INC.
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer effector therapeutic ...
EFFECTOR THERAPEUTICS INC.
Proxy Statement - Form DEF 14A
Def 14a table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange ...
EFFECTOR THERAPEUTICS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer effector therapeutics inc. published t ...
EFFECTOR THERAPEUTICS INC.
Preliminary Proxy Statement - Form PRE 14A
Pre 14a table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange ...
EFFECTOR THERAPEUTICS INC.
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer effector therapeutic ...
EFFECTOR THERAPEUTICS INC.
Supplemental Prospectus - Form 424B3
424b3 filed pursuant to rule 424(b)(3) registration statement no. 333-262339 prospectus supplement no. 1 (to prospectus dated april 2, 2024) effector therapeutics, inc. this prospe ...
EFFECTOR THERAPEUTICS INC.
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer effector therapeutic ...
EFFECTOR THERAPEUTICS INC.
Supplemental Prospectus - Form 424B5
424b5 filed pursuant to rule 424(b)(5) registration statement no. 333-267221 prospectus supplement (to prospectus dated september 9, 2022) $6,762,420 common stock this prospectus s ...
EFFECTOR THERAPEUTICS INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: april 2, 2024 accession number: 00011931 ...
EFFECTOR THERAPEUTICS INC.
Post-Effective Amendment to Registration Statement - Form POS AM
Pos am table of contents as filed with the securities and exchange commission on march 29, 2024 registration no. 333-262339 united states securities and exchange commission washing ...
EFFECTOR THERAPEUTICS INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
S-8 as filed with the securities and exchange commission on march 28, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-8 re ...
EFFECTOR THERAPEUTICS INC.
Annual Report for Fiscal Year Ending --12-31, 2023 (Form 10-K)
10-k united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act o ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti